Sheng-li Xue, Md

This study tests a drug called inotuzumab ozogamicin in people with acute lymphoblastic leukemia (ALL) who still have tiny amounts of cancer cells (called minimal residual disease, or MRD) after a stem cell transplant. The goal is to see if the drug can clear these remaining cell…